BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be Wrong

BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be Wrong

There might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.